Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Non-Current Deffered Revenue (2020)

Ovid Therapeutics' Non-Current Deffered Revenue history spans 1 years, with the latest figure at $10.2 million for Q4 2020.

  • For Q4 2020, Non-Current Deffered Revenue changed N/A year-over-year to $10.2 million; the TTM value through Dec 2020 reached $10.2 million, changed N/A, while the annual FY2020 figure was $10.2 million, N/A changed from the prior year.
  • Non-Current Deffered Revenue reached $10.2 million in Q4 2020 per OVID's latest filing, up from $9.9 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $10.2 million in Q4 2020 to a low of $9.9 million in Q3 2020.